BE A PART OF THE FAPI COMMUNITY

www.sofie.com
Data in more than 5,000 patients supports the utility of FAPI (Fibroblast Activation Protein Inhibitors) to improve diagnosing oncological and non-oncological disease. Originally developed by scientists at University Clinic Heidelberg (the same team responsible for PSMA). FAPI is a family of radiopharmaceuticals that target the fibroblast activation protein.

SOFIE has licensed the rights to the diagnostic and companion diagnostic utility of the FAPI compounds with FAPI-46 as its lead $^{68}$Ga labeled and FAPI-74 as its $^{18}$F labeled compound. Both have demonstrated favorable biodistribution and dosimetry, target-specific uptake, excellent tumor to background ratio, and no toxicity observed in animal models and human subjects.

In the US, SOFIE is leading the clinical development of $^{68}$GaFAPI-46 and $^{18}$FFAPI-74 and has active INDs for Phase 2 studies currently in progress. In addition to SOFIE sponsored efforts, we are also engaged with more than 120 academic institutions in 39 countries to support clinical research studies.
**SOFIE Sponsored Clinical Research Program**

**[\(^{18}\text{F}\)]FAPI-74**
- Gastrointestinal Cancers
  - Phase 2 active (NCT05641896)

**[\(^{68}\text{Ga}\)]FAPI-46**
- Pancreatic Cancer
  - Phase 2 active (NCT05262855)

**SOFIE FAPI Global Outreach Program**
- 212 Studies being conducted by 123 sites globally

**Oncology**

**Non-Oncology:**
- Examples: Fibrotic disease, Immune mediated and Cardiovascular
We are pleased to offer our academic community the use of FAPI as a diagnostic or companion diagnostic tool.

**[¹⁸F]FAPI-74**

- Automated synthesis cassettes available through the Trasis system
- Pursue your own IND through a letter of cross reference to the SOFIE IND

**[⁶⁸Ga]FAPI-46**

- Pursue your own IND through a letter of cross reference to the SOFIE IND
Expand your research program and grant opportunities

Technical manufacturing assistance to get you started

GMP grade precursor in support of your investigator-initiated trial
2019 SNMMI Image of the Year
F Giesel et al, SNMMI 2019, Abstract 289

2021 JNM Best Overall Article

2022 SNMMI Image of the Year
J Diekmann et al, SNMMI 2022, Abstract 413
SOFIE’s vision is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (theranostics). With our robust pharmaceutical production and distribution network, mature contract manufacturing services, and now, high value intellectual property, we are poised to deliver on the promise of radiopharmaceuticals from start to clinic.

**CONTACT US:**

Sangeeta Kalra  
Associate Director, FAPI Global Outreach Program  
sangeeta.kalra@sofie.com

All other inquiries, visit www.sofie.com/fapi-development or email FAPIprogram@sofie.com